Official Name: AbbVie Inc.

Headquarters: North Chicago, IL, United States

Founded: 2013

Employees: 50,000

CEO: Mr. Richard A. Gonzalez

NYSE: ABBV -1.01%

Market Cap

$285.06 Billion

USD as of Jan. 1, 2024

Market Cap History

Company Description

AbbVie Inc. is a pharmaceutical company. It is dedicated to the research and development, manufacturing, and marketing of medicine for a number of chronic diseases including autoimmune diseases, leukemia, lymphoma, hepatitis C, and HIV. It is also engaged in the treatment of pancreatic, thyroidal, and other hormonal insufficiencies.

AbbVie market capitalization over time

Evolution of AbbVie Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of AbbVie Inc.

Detailed Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Top 1-year algo backtest: +191.38%

$10,000 in June 2023 would now be $29,138 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Product & Services

Pharmaceutical drugsHumira (adalimumab)Imbruvica (ibrutinib)Venclexta (venetoclax)Zinbryta (daclizumab)Kaletra (lopinavir)Norvir (ritonavir)Mavyret/Maviret (glecaprevir/pibrentasvir)Skyrizi (risankizumab)

Key People

Richard A. Gonzalez (Chairman and CEO) Michael Severino (Vice Chairman and President)


Revenue: US$56.197 billion (2021)

Operating income: US$17.924 billion (2021)

Net income: US$11.542 billion (2021)

Total assets: US$150.565 billion (2020)

Total equity: US$13.097 billion (2020)



1 North Waukegan Road

North Chicago, IL 60064

United States

Phone: 847 932 7900